Related Experiment Videos
c-myc down-regulates class I HLA expression in human melanomas.
R Versteeg1, I A Noordermeer, M Krüse-Wolters
1Department of Clinical Oncology, Leiden University Hospital, The Netherlands.
The EMBO Journal
|April 1, 1988
Summary
High c-myc oncogene expression inversely correlates with class I HLA antigen levels in melanoma. Increasing c-myc reduces HLA expression, impacting melanoma
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Class I HLA antigen expression is often reduced in human tumors.
- Melanoma cell lines exhibit variable class I HLA expression.
- The oncogene c-myc's role in regulating HLA expression is unclear.
Purpose of the Study:
- To investigate the relationship between c-myc oncogene expression and class I HLA antigen levels in melanoma.
- To determine if elevated c-myc expression inhibits class I HLA expression.
- To explore the impact of c-myc on melanoma cell interactions with the immune system.
Main Methods:
- Analysis of c-myc and class I HLA mRNA levels in 11 melanoma cell lines.
- Transfection of a melanoma cell line with a c-myc expression vector.
- Measurement of class I HLA and beta 2-microglobulin mRNA and protein expression.
- Treatment with gamma-interferon to assess restoration of HLA expression.
Main Results:
- An inverse correlation was observed between c-myc and class I HLA mRNA levels.
- Transfection with c-myc led to reduced class I HLA and beta 2-microglobulin mRNA and protein expression.
- Gamma-interferon treatment restored HLA and beta 2-microglobulin expression, preceded by decreased c-myc mRNA.
Conclusions:
- Class I HLA expression in melanoma is modulated by c-myc expression levels.
- High c-myc oncogene expression can downregulate class I HLA, potentially affecting immune surveillance.
- Targeting c-myc may offer therapeutic strategies for melanoma immunotherapy.